Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2016

Open Access 01-12-2016 | Research article

Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients

Authors: Homa Zarrabi, Mohammadrasoul Khalkhali, Azam Hamidi, Reza Ahmadi, Maryam Zavarmousavi

Published in: BMC Psychiatry | Issue 1/2016

Login to get access

Abstract

Background

Over the past few years, methamphetamine-induced psychosis (MIP) has increased in Iran, accounting for a significant percentage of psychiatry hospital admissions. The present study was conducted with an aim to investigate clinical symptoms, and course and treatment methods of MIP inpatients in Shafa Psychiatry Hospital in northern Iran.

Methods

Participants were 152 MIP inpatients. Brief Psychiatric Rating Scale (BPRS) subscales of suspiciousness, unusual thought content; hallucinations and hostility were used to measure psychiatric symptoms. Data regarding suicide and homicide and violence were also obtained through interviews with the inpatients and their family. Based on their lengths of recovery time, the inpatients were categorized into 3 clinical groups. These inpatients received their usual treatments and were monitored for their psychiatric symptoms and clinical course of illness. The data were analyzed by descriptive statistics.

Results

The most frequent psychiatric symptoms were violence (75.6 %), intimate partner violence (61.2 %), delusions of persecution (85.5 %), delusions of reference (38.5 %), delusions of grandiosity (32.9 %), delusions of infidelity (30.2 %), auditory hallucinations (51.3 %), visual hallucinations (18.4 %), suicidal thoughts (14.5 %), homicidal thoughts (3.9 %), suicide attempts (10.5 %) and homicide attempts (0.7 %). Recovery from psychotic symptoms in 31.6 % of the inpatients took more than one month. 46.1% of the inpatients were treated with Risperidone and 37.5 % with Olanzapine. Persecutory delusion and auditory hallucination were the most frequent persistent psychotic symptoms. 20.8 % of the inpatients with duration of psychosis more than one month were treated with electroconvulsive therapy (ECT) along with antipsychotics.

Conclusion

All forms of violence are highly frequent in MIP inpatients. Our finding agrees with many other studies suggesting that recovery from MIP can take more than a month. Initial promising findings were found regarding the efficacy of Electroconvulsive therapy in MIP patients.
Literature
1.
Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric emergency services in Iran. Iran J Psychiatry Behav Sci. 2011;5:1–5.PubMedCentralPubMed
2.
Mehrjerdi ZA, Noroozi A. Methamphetamine intoxication in emergency departments of hospitals in Iran: implications for treatment. Iran J Med Sci. 2013;38(4):347–8.
3.
Shariatirad S, Maarefvand M, Ekhtiari H. Emergence of a methamphetamine crisis in Iran. Drug Alcohol Rev. 2012;32:223–4.CrossRefPubMed
4.
Lecomte T, Mueser KT, MacEwan W, Thornton AE, Buchanan T, Bouchard V, et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. J Nerv Ment Dis. 2013;201(12):1085–9.CrossRefPubMed
5.
Plüddemann A, Dada S, Parry CD, Kader R, Parker JS, Temmingh H, et al. Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. Afr J Psychiatry. 2013;16(1):45–9.
6.
Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine induced psychosis. J Ment Health. 2013;22(4):341–9.CrossRefPubMed
7.
Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 2000;914:1–12.CrossRefPubMed
8.
Yui K, Ikemoto S, Goto K, Nishijima K, Yoshino T, Ishiguro T. Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: susceptibility to psychotic states and implications for relapse of schizophrenia. Pharmacopsychiatry. 2002;35(2):62–71.CrossRefPubMed
9.
Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221.PubMedCentralCrossRefPubMed
10.
Yui K, Ishiguro T, Goto K, Ikemoto S, Kamata Y. Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur Arch Psychiatry Clin Neurosci. 1999;249(2):103–11.CrossRefPubMed
11.
Mehrjerdi ZA. A brief overview of methamphetamine use treatment in Iran: Intervention and practice. J Res Med Sci. 2013;18(12):1018–20.PubMed
12.
Grelotti DJ, Kanayama G, Pope Jr HG. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry. 2010;167(1):17–23.CrossRefPubMed
13.
McKetin R, McLaren J, Lubman DI, Hides L. Hostility among methamphetamine users experiencing psychotic symptoms. Am J Addict. 2008;17(3):235–40.CrossRefPubMed
14.
Mehrjerdi ZA, Barr AM, Noroozi A. Methamphetamine-associated psychosis: a new health challenge in Iran. Daru. 2013;21(1):30.CrossRef
15.
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003;6(4):347–52.CrossRefPubMed
16.
Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):959–64.CrossRefPubMed
17.
McKetin R, Lubman DI, Najman JM, Dawe S, Butterworth P, Baker AL. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study. Addiction. 2014;109(5):798–806.CrossRefPubMed
18.
Straus H, Cerulli C, McNutt LA, Rhodes KV, Conner KR, Kemball RS, et al. Intimate partner violence and functional health status: associations with severity, danger, and self-advocacy behaviors. J Womens Health (Larchmt). 2009;18(5):625–31.CrossRef
19.
Cartier J, Farabee D, Prendergast ML. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J Interpers Violence. 2006;21(4):435–45.CrossRefPubMed
20.
Ernst AA, Weiss SJ, Enright-Smith S, Hilton E, Byrd EC. Perpetrators of intimate partner violence use significantly more methamphetamine, cocaine, and alcohol than victims: a report by victims. Am J Emerg Med. 2008;26(5):592–6.CrossRefPubMed
21.
Martin I, Palepu A, Wood E, Li K, Montaner J, Kerr T. Violence among street-involved youth: the role of methamphetamine. Eur Addict Res. 2009;15(1):32–8.CrossRefPubMed
22.
Stretesky PB. National case–control study of homicide offending and methamphetamine use. J Interpers Violence. 2009;24(6):911–24.CrossRefPubMed
23.
Cohen JB, Dickow A, Horner K, Zweban JE, Balabis J, Vandersloot D, et al. Methamphetamine dependence. Am J Addict. 2003;12(5):377–85.CrossRefPubMed
24.
Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for women and man. Am J Prev Med. 2002;23:260–8.CrossRefPubMed
25.
Foran HM, O’Leary KD. Alcohol and intimate partner violence: a meta-analytic review. Clin Psychol Rev. 2008;28(7):1222–34.CrossRefPubMed
26.
27.
Leviel V. Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem. 2011;118(4):475–89.CrossRefPubMed
28.
Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. Int Rev Neurobiol. 2009;88:43–64.CrossRefPubMed
29.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085–99.CrossRefPubMed
30.
Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG. Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. Am J Addict. 2015;24(7):586–9. doi:10.​1111/​ajad.​12274.CrossRefPubMed
31.
32.
Niemi-Pynttäri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94–9. doi:10.​4088/​JCP.​12m07822.CrossRefPubMed
33.
34.
Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002;23(2):145–50.CrossRefPubMed
35.
Haile CN, Kosten TR, Kosten TA. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse. 2009;35(3):161–77.PubMedCentralCrossRefPubMed
36.
Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev. 2013;32(5):449–60.PubMedCentralPubMed
37.
Sulaiman AH, Gill JS, Said MA, Zainal NZ, Hussein HM, Guan NC. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract. 2013;17(2):131–8.CrossRefPubMed
38.
Seddigh R, Keshavarz-Akhlaghi AA, Shariati B. Treating methamphetamine-induced resistant psychosis with clozapine. Case Rep Psychiatry. 2014;2014:845145.PubMedCentralPubMed
39.
Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse. 2014;40(1):10–5.CrossRefPubMed
40.
Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76(8):1169–74.PubMed
41.
Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, et al. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend. 2015;148:158–64.CrossRefPubMed
42.
Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253–62.CrossRefPubMed
43.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Methamphetamine Treatment Project. Identifying methamphetamine users at risk for major depressive disorder: findings from the methamphetamine treatment project at three-year follow-up. Am J Addict. 2008;17(2):99–102.CrossRefPubMed
44.
Callor WB, Petersen E, Gray D, Grey T, Lamoreaux T, Bennett PJ. Preliminary findings of noncompliance with psychotropic medication and prevalence of methamphetamine intoxication associated with suicide completion. Crisis. 2005;26(2):78–84.CrossRefPubMed
45.
Kuo CJ, Tsai SY, Liao YT, Conwell Y, Lin SK, Chang CL, et al. Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case–control study. J Clin Psychiatry. 2011;72(4):487–93.CrossRefPubMed
46.
Wang LJ, Chiang SC, Su LW, Lin SK, Chen CK. Factors associated with drug-related psychiatric disorders and suicide attempts among illicit drug users in Taiwan. Subst Use Misuse. 2012;47(10):1185–8.CrossRefPubMed
47.
48.
Pasic J, Russo JE, Ries RK, Roy-Byrne PP. Methamphetamine users in the psychiatric emergency services: a case–control study. Am J Drug Alcohol Abuse. 2007;33(5):675–86.CrossRefPubMed
49.
Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991–1002. Review.CrossRefPubMed
50.
Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R. Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009;197(4):225–31.PubMedCentralCrossRefPubMed
51.
McKetin R, Lubman DI, Lee NM, Ross JE, Slade TN. Major depression among methamphetamine users entering drug treatment programs. Med J Aust. 2011;195(3):S51–5.PubMed
52.
Cloutier RL, Hendrickson RG, Fu RR, Blake B. Methamphetamine-related psychiatric visits to an urban academic emergency department: an observational study. J Emerg Med. 2013;45(1):136–42.CrossRefPubMed
53.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict. 2008;17(1):24–7.CrossRefPubMed
54.
Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181–90.CrossRefPubMed
55.
Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci. 2000;12(4):480–4.CrossRefPubMed
Metadata
Title
Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients
Authors
Homa Zarrabi
Mohammadrasoul Khalkhali
Azam Hamidi
Reza Ahmadi
Maryam Zavarmousavi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-016-0745-5

Other articles of this Issue 1/2016

BMC Psychiatry 1/2016 Go to the issue

Study protocol

Effectiveness of enhanced cognitive behavioral therapy (CBT-E) in the treatment of anorexia nervosa: a prospective multidisciplinary study

Study protocol

Impact of peer-led quality improvement networks on quality of inpatient mental health care: study protocol for a cluster randomized controlled trial

Research article

Smaller gray matter volume of hippocampus/parahippocampus in elderly people with subthreshold depression: a cross-sectional study

Study protocol

Clinical trial of modulatory effects of oxytocin treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-controlled, double-blind and crossover trial

Research article

Development and validation of a contextual measure of functioning for people living with severe mental disorders in rural Africa

Research article

Service user views of spiritual and pastoral care (chaplaincy) in NHS mental health services: a co-produced constructivist grounded theory investigation